Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — PAC Partners Inaugural Healthcare Conference 2022
24 slides from Island Pharmaceuticals's conference presentation, Apr 5, 2022
Slide 1: Updated investor presentation and conference participation
5 April 2022 For personal use only ASX Announcement Updated investor presentation and conference participation MELBOURNE Australia, 5 April 2022: Australian mid-clinical stage antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to release a c
Slide 2: Solving Urgent Viral Disease Threats
For personal use only SOLVING URGENT VIRAL DISEASE THREATS (ASX: ILA) PAC Partners Inaugural Healthcare conference – April 2022 ISLAND PHARMACEUTICALS LIMITED 1 InvestorPRESENTATION INVESTOR Presentation – October 2021 – APRIL 2022
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited views on its future performance or condition. Actual results could differ No representation, warranty or assurance (express or implied) is given or For personal use only (ABN 641 183 842) (Company or Island Pharmaceutic
Slide 4: Island at a Glance
ISLAND AT A GLANCE For personal use only Island Pharmaceuticals (ASX: ILA) is a mid clinical-stage drug repurposing company, focused on the rapid development of antiviral therapeutics for infectious diseases • Rapidly advancing lead drug ISLA-101 toward Phase 2 “PEACH”* clinical trial for the treatm
Slide 5: The Benefits of Drug Repurposing
THE BENEFITS OF DRUG REPURPOSING For personal use only ISLAND PHARMACEUTICALS LIMITED 4 InvestorPRESENTATION INVESTOR Presentation – October 2021 – APRIL 2022
Slide 6: The Challenge
For personal use only THE CHALLENGE ISLAND PHARMACEUTICALS LIMITED 5 InvestorPRESENTATION INVESTOR Presentation – October 2021 – APRIL 2022
Slide 7: Mosquito Borne Viruses: Global Challenges
MOSQUITO BORNE VIRUSES: GLOBAL CHALLENGES For personal use only Nov 23, 2021 Nov 17, 2021 Dec 1, 2021 The researchers found 2.4 times the rate of arbovirosis as originally reported, including coinfections, suggesting underestimation of the incidence of the three viruses. However, future research is
Slide 8: Why Dengue as a First Target for ISLA-101?
WHY DENGUE AS A FIRST TARGET FOR ISLA-101? SIGNIFICANT UNMET NEED FOR DISEASE WITH INCREASING INCIDENCE For personal use only Significant unmet need (3.9 billion people at risk) Increasing spread to US, EU and Australia ISLA-101 has both therapeutic and prophylactic potential Strong animal and human
Slide 9: Dengue Is a Widespread Issue
DENGUE IS A WIDESPREAD ISSUE For personal use only Dengue outbreaks occurred in many countries of the world in the Americas, Africa, the Middle East, Asia, and the Pacific Islands. ISLAND PHARMACEUTICALS LIMITED https://www.healthmap.org/dengue/en/ 8 InvestorPRESENTATION INVESTOR Presentation – Octo
Slide 10: Dengue in 2050 – A Global Disease
DENGUE IN 2050 – A GLOBAL DISEASE For personal use only Prediction based on projections of future temperatures, rainfall, and mosquito populations (NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford.) ISLAND PHARMACEUTICALS LIMITED https://earthobserv
Slide 11: Limited Available Solutions
LIMITED AVAILABLE SOLUTIONS HIGHLY PREVALENT DISEASES WITH UNMET MEDICAL NEED For personal use only Deformities in babies from mothers with Zika Dengue Zika Yellow Japanese West Nile fever Virus fever Encephalitis Viral diseases are a Worldwide 390 Up to n/a 130,000 70,000 leading cause of prevalenc
Slide 12: ISLA-101
For personal use only ISLA-101 ISLAND PHARMACEUTICALS LIMITED 11 InvestorPRESENTATION INVESTOR Presentation – October 2021 – APRIL 2022
Slide 13: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT DEMONSTRATED ACTIVITY AGAINST FLAVIVIRUSES (A SUBGROUP OF ARBOVIRUSES) IN MULTIPLE MODELS OF INFECTION For personal use only • In in-vitro models using fresh human cells, Dengue 1-4 ISLA-101 has demonstrated broad anti-viral activity • In animal models, ISLA-101 is pr
Slide 14: Nearing IND Submission
NEARING IND SUBMISSION IND IS A CRITICAL REGULATORY MILESTONE, ENABLING PEACH STUDY COMMENCEMENT For personal use only Sponsor information (complete) Drug manufacturing Summary of existing (almost complete) human data (complete) Drug substance (API) ~45 previous clinical • Drug product trials
Slide 15: World Class Team in Place
WORLD CLASS TEAM IN PLACE TEAM ASSEMBLED WITH DOMAIN EXPERTISE IN CLINICAL TRIALS AND MANUFACTURING For personal use only Sponsor Key Island people overseeing the ISLA-101 PEACH study Teresa Byrne, Vice President Larry Norder, CMC Consultant Clinical Product Development. Overseeing clinical developm
Slide 16: Key Collaborations & Alliances
KEY COLLABORATIONS & ALLIANCES SUPPORTING FUTURE PIPELINE DEVELOPMENT For personal use only Research Collaboration Agreement to screen thousands of known molecules against host targets building upon the Fenretinide (ISLA-101) discovery sourced from these laboratories that the Company has licensed fo
Slide 17: Pathway / Timing to Clinical Trials
PATHWAY / TIMING TO CLINICAL TRIALS MULTIPLE WORKSTREAMS WILL TAKE US TO FDA REVIEW OF OUR IND For personal use only 1. Manufacturing of clinical product 2. Finalization of CMC section of IND IND Mandatory Island trial submitted 30-day commences!* 3. Completion of Protocol review period at FDA ISLAN
Slide 18: Phase II Dengue (PEACH) Trial Study in Detail
PHASE II DENGUE (PEACH) TRIAL STUDY IN DETAIL “PEACH" STUDY- A PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY FOR THE PROPHYLACTIC EXAMINATION OF AN ANTIVIRAL IN A DENGUE CHALLENGE MODEL For personal use only Administer ISLA-101 daily Phase II trial protocol Up to 4 cohorts/4 arms Incl
Slide 19: The Commercial Opportunity
For personal use only THE COMMERCIAL OPPORTUNITY ISLAND PHARMACEUTICALS LIMITED 18 InvestorPRESENTATION INVESTOR Presentation – October 2021 – APRIL 2022
Slide 20: Commercial Opportunity
COMMERCIAL OPPORTUNITY For personal use only Prophylactic for National Government Priority Review travelers Military outbreaks Stockpiles Voucher Tropical area travellers opportunity: Military opportunity: Endemic area opportunity: • Comparable to malaria market – • Isla is partnering with army (CRA
Slide 21: Advancing Our Pipeline
ADVANCING OUR PIPELINE For personal use only Island has recently engaged a third party virologist to Exemplary viruses that met these criteria include: investigate ~150 human relevant viruses, prioritised by: • Zika virus Medical relevance for the Americas, Europe, • Human respiratory syncytial viru
Slide 22: Upcoming Milestones
UPCOMING MILESTONES For personal use only H1 FY 2022 H2 FY 2022 H1 FY 2023 H2 FY 2023 • Drug substance • File IND • Advance through Sign SUNY CTA PEACH cohorts manufactured • Open IND Announce Principal • Trial read out Investigator • Analytical method • Start screening development • Meeting wit
Slide 23: Board, Management & Scientific Board
BOARD, MANAGEMENT & SCIENTIFIC BOARD For personal use only MANAGEMENT TEAM & BOARD OF DIRECTORS Dr. David Foster Dr. Anna Lavelle Mr. Al Hansen Dr. Paul MacLeman Dr. David Brookes CEO & Executive Non-Executive Non-Executive Executive Chair Non-Executive Director Director Director Director SCIENTIFIC
Slide 24: Contact
For personal use only David Foster Chief Executive Officer & Executive Director david@islapharma.com Authorized for release by Paul MacLeman, Executive Chairman Island Pharmaceuticals www.islapharma.com Limited Registered office: Suite 201, ISLAND PHARMACEUTICALS 697 Burke Rd, Camberwell VIC 3124, A
Island Pharmaceuticals — PAC Partners Inaugural Healthcare Conference 2022 on 6ix